January 31, 2018 / 8:32 AM / 24 days ago

BRIEF-Oncology Venture Announces Positive Interim Results From A Phase 1/2 Study

Jan 31 (Reuters) - ONCOLOGY VENTURE SWEDEN AB:

* ANNOUNCES POSITIVE INTERIM RESULTS FROM A PHASE 1/2 STUDY WITH LIPLACIS AND ITS DRP IN HEAVILY PRETREATED METASTATIC BREAST CANCER PATIENTS

* STUDY IS PROGRESSING ACCORDING TO PLAN, AND LAST PATIENT IS EXPECTED TO BE INCLUDED BEFORE END OF Q1 2018.

* ‍LAST PATIENT IS EXPECTED TO BE INCLUDED BEFORE END OF Q1 2018.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below